These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31396487)

  • 1. Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.
    McCartney A; Migliaccio I; Bonechi M; Biagioni C; Romagnoli D; De Luca F; Galardi F; Risi E; De Santo I; Benelli M; Malorni L; Di Leo A
    Front Oncol; 2019; 9():666. PubMed ID: 31396487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence.
    Polk A; Kolmos IL; Kümler I; Nielsen DL
    ESMO Open; 2016; 1(6):e000093. PubMed ID: 28848657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
    D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D
    Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer.
    Zhao S; Zhang H; Yang N; Yang J
    Transl Cancer Res; 2023 Jun; 12(6):1617-1634. PubMed ID: 37434680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.
    Krasniqi E; Goeman F; Pulito C; Palcau AC; Ciuffreda L; Di Lisa FS; Filomeno L; Barba M; Pizzuti L; Cappuzzo F; Sanguineti G; Maugeri-Saccà M; Ciliberto G; Fanciulli M; Blandino G; Vici P
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
    Abdel-Razeq H; Sharaf B
    Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.